Sanofi (NASDAQ: SNY) reported Q2 EPS of EUR1.73, EUR0.84 better than the analyst estimate of EUR0.89. Revenue for the quarter came in at EUR10.74 billion versus the consensus estimate of EUR11.68 billion.

GUIDANCE

2024 business EPS(1) to be stable at CER(2), an upgrade from a low single-digit percentage decrease previously, underpinned by accelerated delivery of Sanofi’s pipeline-driven transformation. Applying the average July 2024 exchange rates, the currency impact on 2024 business EPS is c.-5.5% to -6.5%.

For earnings history and earnings-related data on Sanofi (SNY) click here.